DNA ENCODED LIBRARY TECHNOLOGY FOR DRUG DISCOVERY (HB 2025). This item is unavailable.
Language: English
Published by RSC PUBLISHING (NP), 2025
- Hardcover
- Used

Seller: UK BOOKS STORE, London, London, United KingdomUK BOOKS STORE
AbeBooks seller since March 11, 2024
Condition: Used
US$ 301.03
Item description from seller
Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.
Seller Inventory # CBS 9781788014878
- Title
- DNA ENCODED LIBRARY TECHNOLOGY FOR DRUG DISCOVERY (HB 2025)
- Author
- LIU G
- Publisher
- RSC PUBLISHING (NP)
- Publication year
- 2025
- Condition
- New Books
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 1788014871
- ISBN 13
- 9781788014878
- Edition
- International Edition
DNA-encoded libraries have numerous advantages over traditional screening methods, including easy identification of compounds and the large quantity of compounds that can be screened simultaneously.
This book provides a comprehensive guide to the implementation of DNA-encoded library technology (DELT) in drug discovery for screening and hit validation, illustrated with successful case studies.
A valuable resource for researchers in drug discovery, this book is complete with successful case studies to illustrate the best practice in implementation and operation of DELT.
"Synopsis" may belong to another edition of this title.
About the Author
Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.
"About the title" may belong to another edition of this title.